Revisiting ABO incompatibility as a risk factor for significant neonatal hyperbilirubinemia

Abstract

Babies with ABO incompatibility are often advised frequent biochemical screening and prolonged hospital stay. Our primary objective of the study was to compare serum bilirubin levels at 48 h and 96 h of age in neonates with and without ABO incompatibility. Our prospective study included neonates with gestation ≥ 34 weeks, with or without ABO incompatibility (92 in each group). A direct Coombs test was performed on cord blood. The mean serum bilirubin and haematocrit levels in both groups at 48 h and 96 h were comparable. The mean reticulocyte count of babies with ABO incompatibility was, however, significantly higher. Late preterm and term neonates with and without ABO incompatibility have similar bilirubin levels and no increased risk of significant hyperbilirubinemia. Prolonged hospitalisation of these neonates appears to be unnecessary.

Keywords

ABO incompatibility neonates neonatal hyperbilirubinemia

Introduction

Neonatal hyperbilirubinemia is the most common clinical condition requiring evaluation and treatment in neonates and is a frequent cause for readmission during the first postnatal week of life. ABO haemolytic disease has been recognised as a major risk factor.^1,2 Although this occurs in 20–25% of pregnancies, only a small fraction of these babies require intervention, namely those with ABO haemolysis.³

ABO incompatibility can present with a spectrum of completely asymptomatic disease to severe haemolysis.⁴ Certain factors have been implicated in increasing the risk of hyperbilirubinemia: a positive direct Coombs test (DCT) being one, though with conflicting evidence.^5,6 The American Academy of Pediatrics (AAP) recommends thorough clinical assessment and preferably a biochemical screening of all newborns for jaundice before discharge, especially if they are discharged before the age of 72–96 h. Furthermore, in babies with ABO incompatibility, AAP advises cord blood sampling for blood group typing and DCT before discharge.⁷ The National Neonatology Forum (NNF) stresses a complete clinical assessment and, if feasible, biochemical testing for jaundice before discharge of all newborns.⁸ In neonates with ABO incompatibility, adherence to these guidelines is even more strongly encouraged. However, in low-resource settings, this advice may not be appropriate.

In India, the government is making tremendous efforts in encouraging institutional deliveries through programmes such as Janani Suraksha Yojana (JSY).⁹ The India Newborn Action Plan (INAP) aims to bring down neonatal mortality to single digits by 2030.¹⁰ Implementation of these programmes will lead to increased bed occupancy in hospitals. Steps therefore need to be taken to reduce the burden on the health system without jeopardising neonatal health. Making mother–baby dyads with ABO incompatibility stay in hospital for a longer period and perform biochemical screening and frequent follow-up not only adds to the burden on the health system but also increases the cost of hospitalisation, putting extra pressure on hospital laboratories as well as added expenses for the parents. We therefore conducted this study to see if these babies are actually in need of intensive monitoring.

Participants and methods

Our prospective study was conducted in the Division of Neonatology, Department of Pediatrics of a tertiary care teaching hospital from April 2014 to March 2015. We compared mean serum bilirubin levels between neonates with and without ABO incompatibility in the early neonatal period. The primary objective was their comparison at the ages of 48 h and 96 h; the secondary objectives were to compare haematocrit, Coombs positivity, reticulocyte count, peripheral smear findings, number of babies requiring phototherapy and exchange transfusion.

Neonates with a gestation ≥34 weeks, born to mothers with O Rh positive blood group, were enrolled in the study. These babies were divided into two groups. Group1 included babies with blood group A or B and group 2 included babies with blood group O.

Babies with birth asphyxia (Apgar score ≤7), clinical sepsis, respiratory distress with Down’s score >2/10, clinical pallor, shock and bleeding from skin or mucosal membranes, direct hyperbilirubinemia, congenital anomalies and chromosomal disorders were excluded.

Blood group and DCT were performed on the cord blood of babies born to mothers with O Rh positive blood group. Serum bilirubin, haematocrit, peripheral smear examination and reticulocyte count were measured in all babies aged 48 ± 2 h. Serum bilirubin and haematocrit levels were repeated at the age of 96 ± 2 h. Babies were followed up during their hospital stay; serum bilirubin and haematocrit levels were repeated whenever they appeared clinically jaundiced. These babies were managed either with phototherapy or exchange transfusion according to AAP guidelines.¹¹

Serum bilirubin levels were measured using a photospectrometric microbilirubinometre. Haematocrit levels were measured in the red blood cell column in the centrifuged capillary. Reticulocyte count was performed using new methylene blue dye. A peripheral smear was prepared using Wright’s stain and was reported by our hospital pathologist.

Using the study by Yaseen et al., in which the mean bilirubin level in term ABO-incompatible neonates aged 96 h was reported as 188 ± 80 µmol/dL,¹² and assuming that babies without ABO incompatibility will have serum bilirubin levels 34 µmol/dL lower, to reach a power of 80% and level of significance 5%, the sample size was calculated to be 77 in each group. Considering attrition of 20% during the study, we determined to have 92 in each group.

Statistical analysis was done using SPSS software version 20.0. A P value <0.05 was considered significant. Unpaired Student’s t-test was used to compare serum bilirubin, haematocrit and reticulocyte count in both the groups.

Results

A total of 184 babies (92 in each group) were enrolled in the study. In group 1, 48 babies had blood group A Rh+ve and 44 had blood group B Rh +ve. Both the groups were comparable in terms of baseline demographic profile, namely, anthropometry, gender ratio and gestational age (Table 1).

Table 1.

Baseline demographic profile of neonates with and without ABO incompatibility setting.

	Group 1 (n = 92)	Group 2 (n = 92)
Weight (kg) (mean ± SD)	2.76 ± 0.37	2.8 ± 0.27
Length (cm) (mean ± SD)	47.4 ± 4.52	47.15 ± 2.12
Head circumference (cm) (mean ± SD)	32.35 ± 1.57	32.34 ± 1.33
Male : Female	53 : 39	58 : 34
Late preterm : Term	28 : 64	27 : 65

Table 2 shows mean bilirubin levels between babies with and without ABO incompatibility at 48 h and 96 h of age. There was no statistically significant difference.

Table 2.

Serum bilirubin levels at 48 h and 96 h in two groups.

Groups	Serum bilirubin (µmol/dL) (mean ± SD)
Groups	48 h	96 h
Group 1 (n = 92)	196 ± 73	195 ± 66
Group 2 (n = 92)	177 ± 59	180 ± 60
P value	0.054	0.106

P value < 0.05 is significant (statistical analysis is performed using unpaired t-test).

Mean haematocrit levels of babies between the two groups at 48 h and 96 h of life were also comparable. Interestingly, reticulocyte counts of babies with ABO incompatibility was significantly higher than those without (P value < 0.01) (Table 3).

Table 3.

Haematocrit and reticulocyte count (RC) in two groups.

Infants	Haematocrit (%) (mean ± SD)		RC (% of RBCs) (mean ± SD) 48 h
Infants	48 h	96 h	RC (% of RBCs) (mean ± SD) 48 h
Group 1 (n = 92)	54.25 ± 5.33	51.98 ± 5.32	3.56 ± 1.20
Group 2 (n = 92)	53.91 ± 4.36	51.99 ± 4.30	2.70 ± 1.10
P value	0.641	0.977	<0.001*

P value <0.05 is significant (statistical analysis is performed using unpaired t-test).

The number of babies who received phototherapy in both the groups did not show significant difference: 22 (23.9%) in group 1 and 16 (17.3%) babies in group 2 (P = 0.275). The mean pre-phototherapy serum bilirubin levels in babies who received phototherapy was also compared in both groups (311 ± 50 µmol/dL with ABO incompatibility and 253 ± 20 µmol/dL without) which was statistically significant. The mean age for starting phototherapy in group 1 was 57.8 ± 17.6 h and in group 2 57.0 ± 19.4 h (P = 0.895).

The DCT was positive in only two babies (0.02%); thus, a comparative statistical analysis of different variables could not be done. Both DCT positive babies underwent exchange transfusion at 48 h and 46 h of life, at serum bilirubin levels of 462 and 376 µmol/dL, respectively.

Discussion

The NNF recommends a thorough clinical assessment and if feasible, biochemical screening of all the neonates before discharge. However, data to support NNF protocols are lacking in India.^12,13

We could not find many studies describing the trend of bilirubin levels in babies with ABO incompatibility and any risk factors predicting development of hyperbilirubinemia needing intervention in these babies. Furthermore, no clear guidelines on whether babies with ABO incompatibility should be subjected to a longer postnatal stay in hospital exist. Despite a report from 1996 that babies with ABO incompatibility are at twice the risk of needing intervention in the form of phototherapy compared to normal babies,¹⁴ our results are contrary. Exchange transfusion was rarely needed, an observation similar to ours.¹⁴

In contrast to previous studies, we did not find significant haemolysis, lower haemoglobin levels, lower haematocrit or red blood cell count.^15–17 However, significant reticulocytosis was observed in ABO incompatibility as previously reported.¹⁶ This may be explained by subclinical haemolysis, although bilirubin levels did not rise to levels requiring intervention.

Conflicting studies exist on the role of DCT in ABO incompatibility; we cannot really comment on this, although the only two babies whose bilirubin reached levels needing exchange transfusion had positive tests.

Conclusion

In a resource-poor country, the burden of expensive protocols must be weighed by their practicality and usefulness. Although further multicentric studies with larger sample size over wider ranges of population with varying ethnicity are required to modify the guidelines, our study suggest strict adherence to AAP guidelines is unjustified.

Footnotes

Declaration of conflicting interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and publication of this article.

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

References

Mohan SS and Jain L. Case of the late preterm infant. In: Gleason CA and Devaskar SU, editors. Avery’s Diseases of the Newborn. 9th ed. Philadelphia, PA: Saunders Co., 2012: 405–416.

Maisels

Kring

. Length of stay, jaundice and hospital readmission. Pediatrics 1998; 101: 995–998.

Stoll B and Kleigman R. Blood disorders. In: Behrman R, Kleigman R and Jenson H, editors. Nelson Textbook of Pediatrics. 17th ed. Philadelphia, PA: Saunders Co., 2004: 599–608.

Mundy

Bhatia

. Variable clinical presentations of ABO incompatibility in dizygotic twins. Neonatal Netw 2015; 34: 317–319.

Valsami

Politou

Boutsikou

, et al. Importance of direct antiglobulin test (DAT) in cord blood: causes of DAT (+) in a cohort study. Pediatr Neonatol 2014; 56(4): 256–260.

Lucas

. Neonatal jaundice due to ABO incompatibility in Sri Lankan. Indian J Pediatr 1996; 63: 381–384.

American Academy of Pediatrics Subcommittee on Hyperbilirubinemia. Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics 2004; 114: 29–316. Erratum in: Pediatrics 2004; 114: 1138.

National Neonatology Forum, India. Evidence Based Clinical Practice Guidelines. New Delhi: NNF, 2010. Available at: http://babathakranwala.in/iapneochap/uploads/acd-corner/nnf_guidelines-2011.pdf.

National Health Mission. Janani Suraksha Yojana. New Delhi: NHM, 2013. Available at: http://nhm.gov.in/nrhm-components/rmnch-a/maternal-health/janani-suraksha-yojana/background.html.

10.

Ministry of Health and Family Welfare. INAP: India Newborn Action Plan. New Delhi: Ministry of Health and Family Welfare, 2014. Available at: http://nhm.gov.in/images/pdf/programmes/inap-final.pdf.

11.

Maisels

Bhutani

Bogen

, et al. Hyperbilirubinemia in the newborn infant > or = 35 weeks gestation: an update with clarifications. Pediatrics 2009; 124: 1193–1198.

12.

Yaseen

Khalaf

Rashid

, et al.

Does prophylactic phototherapy prevent hyperbilirubinemia in neonates with ABO incompatibility and positive Coombs’ test?

J Perinatol 2005; 25: 590–594.

13.

Okwundu

Okoromah

Shah

. Cochrane Review: Prophylactic phototherapy for preventing jaundice in preterm or low birth weight infants. Evid Based Child Health 2013; 8: 204–249.

14.

Heier

Fugelseth

Lindemann

, et al. Maternal blood group 0 as a risk factor of neonatal hyperbilirubinemia requiring treatment. Tidsskr Nor Laegeforen 1996; 116: 34–36.

15.

Chen

Lin

Yang

, et al. Association of ABO incompatibility with red blood cell indices of cord blood unit. Pediatr Neonatol 2012; 53: 138–143.

16.

Mishra

Padhi

, et al. Hematological profile in neonatal jaundice. J Basic Clin Physiol Pharmacol 2014; 25: 225–228.

17.

Yogev-Lifshitz

Leibovitch

Schushan-Eisen

, et al. Indication of mild hemolytic reaction among preterm infants with ABO incompatibility. Pediatr Blood Cancer 2016; 63: 1050–1053.